Erratum: Significant endothelin release in patients treated with foam sclerotherapy (Dermatologic Surgery (2012) DOI 10.1111/j.1524-4725.2012.02390.x);Significant endothelin release in patients treated with foam sclerotherapy

Dermatologic Surgery

Volumn 38, Issue 5, 2012, Pages 741-747

  Frullini, Alessandro ^a   Barsotti, Maria Chiara ^b   Santoni, Tatiana ^b   Duranti, Emiliano ^c   Burchielli, Silvia ^d,e   Stefano, Rossella Di ^c  

^a Studio Medico Flebologico Dr Frullini   (Italy)

^b Laboratorio di Ricerca Cardiovascolare   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Azienda Ospedaliero Universitaria Pisana   (Italy)

^e FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; FIBRO VEIN; POLIDOCANOL; TETRADECYL SULFATE SODIUM; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; FOAM; HUMAN; LIQUID; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; RAT; SCLEROTHERAPY; SYSTEMIC CIRCULATION; VARICOSIS; VISUAL DISORDER;

EID: 84860609246     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2012.02486.x     Document Type: Erratum

References (55)

1. Cabrera Garrido JR, Cabrera Garcia Olmedo JR, Garcia Olmedo D,. Nuevo metodo de esclerosis en las varices tronculares. Pathologia Vasculares 1993; 1: 55-72.
2. Frullini A,. Foam sclerotherapy: a review. Phlebolymphology 2003; 40: 125-9. (Pubitemid 36869777)
3. Wollmann JC,. Sclerosant foams: Stabilities, physical properties and rheological behavior. Phlebologie 2010; 4: 208-17.
4. O'Hare JL, Earnshaw JJ,. The use of foam sclerotherapy for varicose veins: a survey of the members of the Vascular Society of Great Britain and Ireland. Eur J Vasc Endovasc Surg 2007; 2: 232-5. (Pubitemid 46995771)
5. Bradbury AW, Bate G, Pang K, Darvall KA, et al. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. J Vasc Surg 2010; 4: 939-45.
6. Ouvry P, Allaert FA, Desnos P, Hamel-Desnos C,. Efficacy of polidocanol foam versus liquid in sclerotherapy of the greater saphenous vein: a multicentre randomised controlled trial with a 2-years follow-up. Eur J Vasc Endovasc Surg 2008; 3: 366-70.
7. Rabe E, Otto J, Schliephake D, Pannier F,. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg 2008; 2: 238-45. (Pubitemid 351163086)
8. Figueiredo M, Araujo S, Barros N, Miranda F,. Results of surgical treatment compared with ultrasound-guided foam sclerotherapy in patients with varicose veins: a prospective randomised study. Eur J Vasc Endovasc Surg 2009; 6: 758-63.
9. Darvall KA, Bate GR, Silverman SH, Adam DJ, et al. Medium-term results of ultrasound-guided foam sclerotherapy for small saphenous varicose. Br J Surg 2009; 11: 1268-73.
10. Creton D, Uhl JF,. Foam sclerotherapy combined with surgical treatment for recurrent varicose veins: short term results. Eur J Vasc Endovasc Surg 2007; 5: 619-24. (Pubitemid 46577874)
11. Ceulen RP, Bullens-Goessens YI, Van de Venne SJ, Nelemans PJ, et al. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatol Surg 2007; 3: 276-81. (Pubitemid 46328226)
12. Uurto I, Hannukainen J, Aarnio P,. Single-center experience with foam sclerotherapy without ultrasound guidance for treatment of varicose. Dermatol Surg 2007; 11: 1334-9; discussion 1339. (Pubitemid 47624085)
13. Myers KA, Jolley D, Clough A, Kirwan J,. Outcome of ultrasound-guided sclerotherapy for varicose veins: medium-term results assessed by ultrasound surveillance. Eur J Vasc Endovasc Surg 2007; 1: 116-21. (Pubitemid 44872674)
14. Frullini A, Cavezzi A,. Sclerosing foam in the treatment of varicose veins and teleangectasies: history and analysis of safety and complications. Dermatol Surg 2002; 28: 11-5. (Pubitemid 34101573)
15. Breu FX, Guggenbichler S, Wollman JC,. 2nd European consensus meeting of foam sclerotherapy 2006, Tegernsee Germany. Vasa 2008; 37 (suppl 71): 1-29.
16. Morrison N,. Ultrasound guided foam sclerotherapy: safety and efficacy. Phlebology 2009; 24: 239.
17. Morrison N,. Studies on safety of foam sclerotherapy. In:, Bergan J, Le Cheng V, editor. Foam sclerotherapy: A Textbook. London: Royal Society of Medicine press; 2008. pp. 183-92.
18. Hill D, Hamilton R, Fung T,. Assessment of techniques to reduce sclerosant foam migration during ultrasound-guided sclerotherapy of the great saphenous vein. J Vasc Surg 2008; 4: 934-9.
19. Morrison N,. Foam sclerotherapy, how to improve results and reduce side effects. Phlébologie 2009; 62: 23-34.
20. Morrison N, Neuhardt D, Rogers CR, McEown J, et al. Comparison of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008; 47: 830-6.
21. Forlee MV, Gouden M, Moore DJ, Shanik G,. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43: 162-4. (Pubitemid 43083525)
22. Bush RG, Derrick M, Manjoney D,. Major neurological events following foam sclerotherapy. Phlebology 2008; 23: 189-92.
23. Hartmann K, Harms L, Simon M,. Neurological deficit after foam sclerotherapy. Eur J Vasc Endovasc Surg 2009; 5: 648-9.
24. Bénigni JP,. Sclérothérapie à la mousse et migraines à aura. Phlébologie 2005; 4: 323-4.
25. Künzlberger B, Pieck C, Altmeyer P, Stücker M,. Migraine Ophthalmique with Reversible Scotomas after Sclerotherapy with Liquid 1% Polidocanol. Dermatol Surg 2006; 11: 1410-3. (Pubitemid 44691149)
26. Frullini A, Felice F, Burchielli S, Di Stefano R,. High production of endothelin after foam sclerotherapy: a new pathogenetic hypothesis for neurological and visual disturbances after sclerotherapy. Phlebology 2011; 26: 203-8.
27. Romero JR, Frey JL, Schwamm LH, Demaerschalk BM, et al. Cerebral ischemic events associated with 'bubble study' for identification of right to left shunts. Stroke 2009; 40: 2343-8.
28. Tsivgoulis G, Heliopoulos I, Stamboulis E,. Safety of TCD "Bubble Study". Stroke 2010; 41: 195.
29. Raymond-Martimbeau P,. Transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy. Phlebology 2009; 24: 114-9.
30. Gillet JL, Guedes JM, Guex JJ, Hamel-Desnos C, et al. Etude cesmous: effets secondaires et complications de la sclerotherapy à mousse de la grande et de la petite veinse saphéne. Etude prospective controlée incluant 1025 patients. Phlébologie 2009; 4: 29-39.
31. Gillet JL,. Troubles visuels et neurologiques après injection de mousse sclérosante. Phlébologie 2009; 2: 26-30.
32. Frullini A, Di Stefano R,. High endothelin production after foam sclerotherapy: a new pathogenetic hypotesis for neurological and visual disturbances after sclerotherapy. Proceedings 24th annual congress ACP November 4-7 2010, Orlando, USA.
33. Frullini A,. Commentary: An Investigation into the Influence of Various Gases and Concentrations of Sclerosants on Foam Stability. Dermatol Surg 2011; 1: 17-8.
34. Frullini A, Di Stefano R,. Nuova ipotesi patogenetica per i disturbi neurologici e visivi dopo scleroterapia con schiuma. Veins 2011; 2: 4-7.
35. Gillet JL, Donnet A, Lausecker M, Guedes JM, et al. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology 2010; 25: 261-6.
36. Lowell RC, Gloviczki P, Miller VM,. In vitro evaluation of endothelial and smooth muscle function of primary varicose veins. J Vasc Surg 1992; 5: 679-86.
37. Barber DA, Wang X, Gloviczki PVM,. Characterization of endothelin receptors in human varicose veins. J Vasc Surg 2000; 1: 61-9.
38. Mangiafico RA, Malatino LS, Santonocito M, Spada RS, et al. Plasma endothelin-1 release in normal and varicose saphenous veins. Angiology 1997; 9: 769-74. (Pubitemid 27418034)
39. Yang L, Qi GY, Cao YX, Liu JM, Zhao M,. The relationship between endothelin receptors and chronic venous insufficiency of lower extremities [Article in Chinese]. Zhonghua Wai Ke Za Zhi 2008; 46: 1325-8.
40. Kallela M, Färkkilä MOF,. Endothelin in migraine patients. Cephalalgia 2000; 6: 329-32. (Pubitemid 28384543)
41. Dreier JP, Kleeberg J, Petzold G, Priller J, et al. Endothelin-1 potently induces Leão's cortical spreading depression vivo in the rat. Brain 2002; 1: 102-12.
42. Färkkilä M, Palo J, Saijonmaa O, Fyhrquist F,. Raised plasma endothelin during acute migraine attack. Cephalalgia 2005; 6: 383-4.
43. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR,. Plasma endothelin-1 concentrations in patients with retinal vein occlusions. Br J Ophthalmol 1998; 82: 498-503. (Pubitemid 28266419)
44. Ciulla TA, Pawlyk BS, Harris A, Oberoi A, et al. Endothelin-1-mediated retinal artery vasospasm and the rabbit electroretinogram. J Ocul Pharmacol Ther 2000; 4: 393-8. (Pubitemid 30658881)
45. Haufschild T, Prünte C, Messerli J, Flammer J,. Erhöhter Endothelin-1-Plasmaspiegel bei retinalen Gefäßverschlüssen jüngerer Patienten. Klin Monatsbl Augenheilkd 2004; 5: 357-9.
46. Takei K, Sato T, Nonoyama T, Miyauchi T, Goto K,. Analysis of vasocontractile responses to endothelin-1 in rabbit retinal vessels using an ETA receptor antagonist and an ETB agonist. Life Sci 1993; 6: 111-5.
47. Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alpérovitch A,. Association between migraine and endothelin type A receptor (ETA -231 A/G) gene polymorphism. Neurology 2001; 56: 1273-7. (Pubitemid 32455282)
48. Ziv I, Fleminger G, Djaldetti R, Achiron A, Melamed E, Sokolovsky M,. Increased plasma endothelin-1 in acute ischemic stroke. Stroke 1992; 23: 1014-6.
49. Mascia L, Fedorko L, Stewart DJ, Mohamed F, Terbrugge K, Ranieri VM, Wallace MC, Pluta RM,. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke 2001; 32: 1185-90.
50. Shaller BJ,. The role of endothelin in stroke: experimental data and underlying pathophysiology. Arch Med Sci 2006; 3: 146-58.
51. Hasdai D, Holmes DR Jr, Garratt KN, Edwards WD, Lerman A,. Mechanical pressure and stretch release endothelin-1 from human atherosclerotic coronary arteries in vivo. Circulation 1997; 2: 357-62. (Pubitemid 27056199)
52. Yanagisawa M, Kurihawa H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-5. (Pubitemid 18090241)
53. Abraham D, Dashwood M,. Endothelin-role in vascular disease. Rheumatology 2008; 47: 23-4.
54. Letizia C, Cerci C, Subioli S, Scuro L,. Clemente, Increased plasma endothelin-1 after nicotine consumption in nonsmokers. Clin Chem 1997; 43: 2440-1.
55. Loghin C, Sdringola S, Gould KL,. Does coronary vasodilation after adenosine override endothelin-1-induced coronary vasoconstriction?. Am J Physiol Heart Circ Physiol 2007; 292: 496-502.